Will Timeline’s $100M Bet on Mitopure® Change the Game? Food, Beauty, and Healthspan Up for Redefinition as Cellular Science Gets Funded

Timeline Powers Up with $100 Million Investment to Fuel Cellular Longevity Revolution

Funding for the Future:

Timeline, a health science company pioneering cellular longevity, has secured a momentous $100 million investment.

The round, led by BOLD (Business Opportunities for L’Oréal Development), L’Oréal Groupe’s strategic innovation venture capital fund, empowers Timeline to expand its science, product categories, and reach across food, beauty, and health sectors.

Mitopure®: The Engine of Cellular Rejuvenation:

Timeline’s groundbreaking ingredient, Mitopure®, lies at the heart of its success.

Backed by over 15 years of research and clinical validation, Mitopure® targets a critical cellular longevity pathway by revitalizing the “powerhouses” of cells, the mitochondria.

This translates to optimal energy production, supporting vital functions like muscle strength, cognitive performance, immune resilience, and radiant skin.

Mitopure® offers a holistic approach to extending healthspan and enhancing overall well-being.

Fueling Growth Across Industries:

With the new investment, Timeline aims to propel its innovative science into new territories.

The company plans to expand its product portfolio beyond nutritional supplements to encompass topical skin health solutions.

Additionally, it seeks to delve deeper into the food and beauty industries, weaving its cellular longevity expertise into diverse consumer experiences.

Leading the Charge in Healthspan:

Under the guidance of Co-Founder and Chairman Patrick Aebischer, Timeline stands at the forefront of the burgeoning cellular longevity field.

With Mitopure® as its key weapon, the company has the potential to revolutionize the way we approach health, aging, and well-being.

This investment marks a significant step forward in Timeline’s journey to empower individuals to live longer, healthier, and more vibrant lives.